Treatment with Pinometostat in KMT2A-rearranged cells and xenograft models reduced H3K79me2 levels, leading to decreases expression of KMT2A target genes and selective cytotoxicity toward leukemia cells [45, 46]. This evidence concerns the gene KMT2A and leukemia.